Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
Two Phase 2 trials investigating -endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023Ended... | May 15, 2023
United States Kyle Guse Eric Van Zanten Foundation For The National Institutes Of Health Cancer Biomarkers Consortium Atossa Therapeutics Inc
Source: marketscreener.com